International Chemical Investors Group completes acquisition of Sandoz site

Published: 1-Apr-2016
Manufacturing Ingredients Finance

Sandoz Industrial Products will be renamed Corden BioChem and will be associated with the Corden Pharma Group


International Chemical Investors Group (ICIG) has completed its acquisition of Sandoz Industrial Products, a Frankfurt-Höchst-based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, from Novartis Group.

Sandoz Industrial Products will be renamed Corden BioChem and will be associated with the Corden Pharma Group, the pharmaceutical platform of ICIG.

Corden BioChem will be complementary to both ICIG's pharma activities as well as its fine chemicals activities within the WeylChem Group. The site represents an important additional building block of fermentation-based production technology for ICIG.

ICIG is focused on the continuation and further development of Cordon BioChem with the enzymatic 7-ACA business for antibiotics at the Höchst site, serving customers worldwide as well as the Corden Pharma Latina site in Italy.

  • Companies:
  • CordenPharma
  • Novartis
See more

You may also like

Design & Build

CordenPharma expands early clinical peptide manufacturing offering

Read more
CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Key considerations when investing in an air compressor When choosing an air compressor, many factors should be taken into consideration, including initial cost, maintenance requirements and energy efficiency
  3. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments
  4. Ascend acquires GMP manufacturing site from Beacon Therapeutics The acquisition also incorporates a long-term partnership with Beacon to continue the manufacturing of its products for clinical use
  5. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Design & Build

CordenPharma expands early clinical peptide manufacturing offering

CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers
Manufacturing

CordenPharma launches lipid nanoparticle starter kits

The kits will aid in loss mitigation of high-value payloads during the gene editing journey to market
Finance

Calypso enters into agreement to be acquired by Novartis

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastrointestinal and rheumatology indications
Manufacturing

CPHI Barcelona Snapshot: CordenPharma

At CPHI Barcelona, Dr Kevin Robinson talked to Dr Michael Quirmbach, CEO and President of CordenPharma, about the company’s recent activities and what lies ahead
Manufacturing

CordenPharma increases peptide production capacity

Following the signature of a multi-year large scale peptide manufacturing agreement earlier this year, CordenPharma has announced the inauguration of increased commercial peptide production capacity with newly-upgraded facilities
Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

Unither Pharmaceuticals acquires Novartis' Brazilian manufacturing facility

Unither has acquired Novartis' Brazilian plant São Paulo, Brazil, in order to enlarge its reach on multidose ophthalmic containers, benefitting from the sterile operations facility
Subscribe now